Innate Pharma Advances Oncology Pipeline with Phase 3 Trial Plans and Promising ADC Data
Key Insights
Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for lacutamab in cutaneous T-cell lymphoma (search) in H2 2026, following FDA clearance and Breakthrough Therapy Designation for Sézary syndrome (search).
IPH4502, the company's Nectin-4 (search) antibody-drug conjugate, demonstrates preliminary anti-tumor activity with favorable safety profile in heavily pre-treated patients with advanced solid tumors.
The company faces financial challenges with €44.8 million cash position providing runway only until Q3 2026, prompting negotiations for non-dilutive financing options including pharma partnerships.
Innate Pharma reported significant clinical progress across its oncology pipeline while navigating financial constraints, as the French biotechnology company prepares for multiple Phase 3 trial initiations and data readouts in 2026.
The company's lead asset lacutamab, an anti-KIR3DL2 (search) antibody, received FDA clearance to proceed with the confirmatory Phase 3 TELLOMAK-3 trial in cutaneous T-cell lymphoma (search) (CTCL). The trial is planned for initiation in H2 2026, subject to securing non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures.
Lacutamab Advances Toward Pivotal Trial
The TELLOMAK-3 study represents a critical milestone for lacutamab, designed as an open-label, multi-center, randomized, comparative study evaluating the antibody in patients with Sézary syndrome (search) and mycosis fungoides (search) who have failed at least one prior systemic therapy. The trial includes two distinct cohorts: a confirmatory cohort in Sézary syndrome intended to support potential Accelerated Approval based on existing TELLOMAK Phase 2 data, and a registrational cohort in mycosis fungoides intended to support full approval.
"With the TELLOMAK-3 design finalized and FDA clearance in hand, lacutamab is planned for confirmatory Phase 3 initiation in H2 2026, dependent on current negotiations with pharma partners and royalty structures," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.
The FDA provided encouraging feedback on the TELLOMAK Phase 2 results and the proposed regulatory pathway, which may support an Accelerated Approval in Sézary syndrome (search) once the Phase 3 trial is underway. In February 2025, the FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary syndrome, highlighting the significant unmet medical need in this patient population.
ADC Platform Shows Promise
IPH4502, Innate Pharma's Nectin-4 (search) exatecan antibody-drug conjugate (ADC), is demonstrating encouraging early clinical activity. The IPH4502-101 Phase 1 study, recruiting in France and the United States, is evaluating safety, tolerability, and preliminary anti-tumor activity in advanced solid tumors known to express Nectin-4, including urothelial carcinoma (search), non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
Preliminary anti-tumor activity was observed in heavily pre-treated patients with advanced solid tumors with a favorable safety profile to date. The maximum tolerated dose is currently being explored, with cohort enrichment ongoing at pharmacologically active dose levels, including in patients with urothelial cancer relapsed or refractory to enfortumab vedotin.
"IPH4502, our Nectin-4 (search) exatecan ADC, is progressing rapidly, with early signs of anti-tumor activity in heavily pre-treated patients, including in urothelial cancer post-enfortumab vedotin, where we aim to validate our preclinical hypothesis supporting a differentiated profile versus MMAE-based approaches," Dickinson noted.
Partnership Programs Progress
The company's collaboration with AstraZeneca continues to advance with multiple programs in late-stage development. The PACIFIC-9 Phase 3 trial evaluating durvalumab in combination with monalizumab or AstraZeneca's oleclumab in patients with unresectable, Stage III non-small cell lung cancer (search) is ongoing, with enrollment complete and data readout expected in H2 2026.
Additionally, interim results from the MATISSE Phase 2 trial evaluating IPH5201 (anti-CD39 (search) antibody) in combination with durvalumab and platinum-based chemotherapy in the neoadjuvant lung cancer setting have been selected for an oral presentation in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026.
Financial Challenges and Strategic Focus
Despite clinical progress, Innate Pharma faces significant financial constraints. The company reported a cash position of €44.8 million as of December 31, 2025, with an anticipated cash runway until the end of Q3 2026. This represents a substantial decrease from €91.1 million as of December 31, 2024.
Revenue and other income declined 55.2% to €9.0 million in 2025, primarily due to decreased collaboration revenue. The company reported a net loss of €49.2 million in 2025, comparable to the €49.5 million loss in 2024. Operating expenses decreased 12.1% to €63.0 million, reflecting the company's cost reduction efforts.
As part of its strategic focus, Innate Pharma has streamlined its organization through a workforce restructuring plan, with planned layoffs to be completed in H1 2026. The company is actively pursuing non-dilutive financing options to support its clinical programs, particularly the planned Phase 3 initiation for lacutamab.
Pipeline Optimization
The company has made strategic decisions to optimize its pipeline focus. The IPH6501 Phase 1/2 study in B-cell non-Hodgkin's lymphoma (search) has been discontinued following completion of dose escalation as part of the company's strategic prioritization. Additionally, Sanofi announced deprioritization of SAR'514, a trifunctional anti-BCMA (search) NK-cell engager, though Sanofi retains exclusive development and commercialization rights.
Innate Pharma regained rights to SAR'579/IPH6101 in July 2025 and has initiated a research collaboration to assess next steps for development, providing additional strategic flexibility for the company's ANKET platform.